Safety, Tolerability, Pharmacokinetics and Food Effects of Oral EC5026 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 30, 2021

Primary Completion Date

May 12, 2021

Study Completion Date

November 24, 2021

Conditions
Healthy Adults
Interventions
DRUG

EC5026 oral tablet

"12 subjects will receive a single oral 8 mg dose of EC5026 in two Dosing Periods (one in fed state and one in fasted state) separated by a Washout Period. Subjects in this group will be randomized 1:1 to one of 2 sequences:~* Dosing Sequence A: Subjects will be dosed in a fed state in Dosing Period 1 and in a fasted state in Dosing Period 2, or~* Dosing Sequence B: subjects will be dosed in a fasted state in Dosing Period 1 and in a fed state in Dosing Period 2."

OTHER

Placebo oral tablet

"6 subjects will receive an oral dose of matching placebo in one single Dosing Period. Subjects in this group will be randomized 1:1 to receive placebo under fed or fasted conditions.~Note: Subjects assigned to the placebo arm will not return for a second Dosing Period."

Trial Locations (1)

78744

PPD Phase I Clinic, Austin

All Listed Sponsors
lead

EicOsis Human Health Inc.

INDUSTRY